Conditions: Toxic Epidermal Necrolysis Stevens-Johnson Syndrome
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.

Detailed description:

Arms:
arm 1: Palifermin 60 micrograms/kg/day IV for 3 consecutive days

Interventions: intervention 1: Palifermin
Intervention descriptions: intervention 1: None

Protocol document: